GCG, glucagon, 2641

N. diseases: 441; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination (FRC) of basal insulin and glucagon-like protein-1 receptor agonist (GLP-1 RA) that has demonstrated glycemic and metabolic benefits in patients with type 2 diabetes mellitus (T2DM) in both randomized controlled trials and real-world studies. 31808132 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE A synthetic monomeric peptide triple receptor agonist, termed "Triagonist" that incorporates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (Gcg) actions, was previously developed to improve upon metabolic and glucose regulatory benefits of single and dual receptor agonists in rodent models of diet-induced obesity and type 2 diabetes. 31730763 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Cardiovascular outcome trials (eg, LEADER [Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results], SUSTAIN-6) demonstrated that GLP-1 (glucagon-like peptide 1) analogs including liraglutide reduce the risk of cardiovascular events in type 2 diabetes mellitus. 31747801 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE However, GIP stimulates glucagon secretion even at hyperglycemia in people with T2D, suggesting that inappropriate GIPR activity in α-cells contributes to the pathogenesis of T2D. 31785304 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE One treatment option for T2DM is based on the gut-derived hormone glucagon-like peptide 1 (GLP-1). 31825468 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. 31793165 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Semaglutide is a glucagon-like peptide-1 (GLP-1) analog approved for once-weekly, subcutaneous (s.c.) treatment of T2D. 31769496 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 GeneticVariation disease BEFREE Our hypothesis was that variants in CCK, GLP-1, and TCF7L2 (transcription factor 7-like 2 locus), which is associated with greatest genetic risk for development of type 2 diabetes mellitus, are associated with GE and independently with glucose tolerance. 31691451 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Eight weeks after liraglutide or human umbilical cord mesenchymal stem cell administration, FPG, HbA<sub>1c</sub> , glucagon, body weight, and pancreatic ASK1, JNK, and BAX mRNA and proteins were significantly decreased, and the levels of serum C-p, INS and GLP-1, ratio of insulin positive area, and Bcl-2 expression were significantly increased in three treatment groups compared with T2DM group (P<.05). 31411368 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Recently GIP-GLP-1 co-agonists with powerful effects on glycemic control and body weight in patients with type 2 diabetes have been described. 31838219 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in obesity and bone disease associated with type 2 diabetes. 31682875 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Contrary to GLP-1, the development of effective GIP-based T2D treatments has been hindered by poor bioavailability and attenuation of beta cell responses to GIP in some patients with sub-optimally controlled T2D. 31751656 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Whilst such effects of GIP antagonism are yet to be evaluated in humans, recent studies using combined GIP and GLP-1 agonists have shown weight reduction and improved glycaemic control in people with type 2 diabetes (T2D). 31759125 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE Moreover, L-SGgly can significantly increase (p < 0.01) GLP-1 levels and decrease (p < 0.01) IL-6 levels in T2DM rat serum. 31586692 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE In study B, individuals with T2DM randomly received GLP-1 RA liraglutide (titrated up to 1.8 mg daily) or titrated insulin glargine for 12 wk. 31415908 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Exposure of the small and large intestine to bile acids induces GLP-1 secretion, modulates the composition of the gut microbiota, and reduces postprandial blood glucose excursions in humans with and without T2DM. 31468642 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Glucagon-like peptide-1 (GLP-1) and strategies based on this blood sugar-reducing and appetite-suppressing hormone are used to treat obesity and type-2 diabetes. 31841385 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE The lamprey GLP-1 analogue shows therapeutic promise for treatment of patients with obesity-related Type 2 diabetes. 31539596 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 AlteredExpression disease BEFREE In line with this, the insulinotropic effects of GIP and GLP-1 are impaired in patients with type 2 diabetes, even when administered in supraphysiological doses. 31693916 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Nevertheless, prior animal and human studies on incretin mimetics, glucagon like peptide-1 receptor agonists (GLP-1 RA) approved for T2DM treatment, have provided indirect evidence that they may also ameliorate NAFLD/NASH, whereas dipeptidyl dipeptidase-4 inhibitors (DDP-4i) were not better than placebo in reducing liver fat in T2DM patients with NAFLD. 30961499 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. 31815785 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Both GLP-1 and GIP are substrates of the enzyme dipeptidyl peptidase-4 (DPP-4), and DPP-4 inhibitors, which potentiate their effects on glycaemic control, are now used to treat type 2 diabetes (T2D). 31706956 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE Polyagonist peptides that exert agonism at GIP, GLP-1 and glucagon receptors are also under investigation as potential treatments for obese type 2 diabetes. 31756366 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE GLP-1 also controls glucose homeostasis, which lead to the approval of GLP-1 receptor agonists for treatment of diabetes type II. 31759971 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.400 Biomarker disease BEFREE G-protein coupled glucagon receptors (GCGRs) play an important role in glucose homeostasis and pathophysiology of Type-II Diabetes Mellitus (T2DM). 31443129 2020